CAMBRIDGE, Mass., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced the appointment of Remi A. Menes as chief commercial officer, effective immediately.
Mary Szela, Chief Executive Officer of Aegerion said, “Remi brings extensive pre-launch and launch expertise and a proven ability to develop and lead commercial efforts globally. Commercialization of rare disease therapies takes a targeted approach and requires strong patient focus. Remi’s broad experience implementing holistic, patient-centered programs that demonstrate the value proposition of therapies make him ideally suited to lead our commercial operations globally, including our sales, marketing and market access efforts. We look forward to his contributions as we continue to drive and evolve our global commercial operations, and particularly as we prepare to submit a marketing authorization application for MYALEPT® in the EU by year-end and, upon anticipated marketing approval, launch JUXTAPID® in Japan.”
Remi Menes most recently served as the General Manager of AbbVie Finland, where he was responsible for the Affiliate’s operations and P&L and its flagship product Humira. He also served as Board Member of Pharma Industry Finland. Before joining AbbVie Finland in 2013, Mr. Menes served as Area Commercial Director, Virology & Neonatal Care, Western Europe & Canada at AbbVie Europe. From 2008-2010, he was the Commercial Director, Specialty Products Division and a Member of the Affiliate Leadership Team at Abbott Canada. Between 1990 and 2008, Mr. Menes held a series of roles of increasing responsibility at Merck Frosst Canada Ltd., including Director, Sales & Marketing, in which he led the Canadian launch of SINGULAIR® for Allergic Rhinitis, and Product Manager for SINGULAIR and PROPECIA®/PROSCAR®. He holds an Executive M.B.A. and a B.Sc. in Organic Chemistry with a minor in Business Studies from Concordia University.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
This press release contains forward-looking statements, including statements regarding: the anticipated submission of a marketing authorization application for MYALEPT in the EU and the anticipated approval and launch of JUXTAPID in Japan. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among others: the risk that regulatory authorities in regions or countries where either of our products is not yet approved may refuse to approve such products, such approvals are not made on a timely basis or such approvals impose significant restrictions or require additional development; and the other risks inherent in the commercialization, drug development and regulatory approval process. For additional disclosure regarding these and other risks we face, see the disclosure contained in the "Risk Factors" section of Aegerion's Quarterly Report on Form 10-Q filed on August 9, 2016, and our other public filings with the Securities and Exchange Commission, available on the SEC's website at http://www.sec.gov. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Investors and others should note that we communicate with our investors and the public using our company website (www.aegerion.com) and our investor relations website (http://ir.aegerion.com), including but not limited to company disclosures; investor presentations and FAQs; Securities and Exchange Commission filings; press releases; public conference calls and webcasts. The information that we post on these websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy, Associate Director, Investor & Public Relations 857-242-5024 Amanda.firstname.lastname@example.org
Source:Aegerion Pharmaceuticals, Inc.